Conclusions
emesis
This randomized clinical trial found that although there was no statistically significant difference in the complete response primary outcome, patients receiving weekly fosaprepitant were less likely to experience emesis compared with those receiving fosaprepitant every 3 weeks, especially in the subgroup with a mean brainstem dose of at least 36 Gy. Weekly fosaprepitant was well tolerated and improved quality of life for patients without compromising survival.